Erlotinib hydrochloride (BioDeep_00000743403)
代谢物信息卡片
Erlotinib HCl (OSI-744)
化学式: C22H24ClN3O4 (429.14552540000005)
中文名称: 盐酸埃罗替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl
InChI: 1H
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:53509
- PubChem: 176871
- ChEMBL: CHEMBL1079742
- MeSH: Erlotinib Hydrochloride
- CAS: 183319-69-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zhihuai Chen, Xinqi Wei, Yunru Zheng, Zongwei Zhang, Wang Gu, Wenjun Liao, Hua Zhang, Xiaoying Wang, Jian Liu, Hua Li, Wei Xu. Targeted co-delivery of curcumin and erlotinib by MoS2 nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer.
Journal of nanobiotechnology.
2023 Sep; 21(1):333. doi:
10.1186/s12951-023-02099-4. [PMID: 37717020] - Guanghui Tang, Wei Wang, Xuan Wang, Ke Ding, SoFong Cam Ngan, Jiao-Yu Chen, Siu Kwan Sze, Liqian Gao, Peiyan Yuan, Xiaoyun Lu, Shao Q Yao. Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.
European journal of medicinal chemistry.
2023 Jul; 259(?):115671. doi:
10.1016/j.ejmech.2023.115671. [PMID: 37499291] - Yanshu Liang, Shuang Zhi, Zhixia Qiao, Fancui Meng. Predicting Blood-Brain Barrier Permeation of Erlotinib and JCN037 by Molecular Simulation.
The Journal of membrane biology.
2023 04; 256(2):147-157. doi:
10.1007/s00232-022-00274-6. [PMID: 36441253] - Qian Liang, Miaomiao Gong, Jing-Hua Zou, Ming-Yu Luo, Lu-Lu Jiang, Cheng Wang, Ning-Xiang Shen, Mo-Cong Zhang, Lu Xu, Hui-Min Lei, Ke-Ren Zhang, Rui Zhang, Guanglei Zhuang, Liang Zhu, Hong-Zhuan Chen, Lu Zhou, Ying Shen. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
2023 Mar; 68(?):100957. doi:
10.1016/j.drup.2023.100957. [PMID: 36990047] - Showkat Ahmad Mir, Auwal Muhammad, Archana Padhiary, Nirius Jenen Ekka, Iswar Baitharu, Pradeep Kumar Naik, Binata Nayak. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
Journal of biomolecular structure & dynamics.
2023 Jan; ?(?):1-14. doi:
10.1080/07391102.2023.2171133. [PMID: 36695102] - Amruta Prabhakar Padakanti, Sachin Dattaram Pawar, Pramod Kumar, Naveen Chella. Development and validation of HPLC method for simultaneous estimation of erlotinib and niclosamide from liposomes optimized by screening design.
Journal of liposome research.
2023 Jan; ?(?):1-15. doi:
10.1080/08982104.2022.2162540. [PMID: 36594184] - Zhongkun Zhang, Yirui Huang, Jing Li, Fei Su, Jimmy Chun-Tien Kuo, Yingwen Hu, Xiaobin Zhao, Robert J Lee. Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles.
Advanced healthcare materials.
2022 Nov; ?(?):e2202412. doi:
10.1002/adhm.202202412. [PMID: 36412002] - Beiyuan Hu, Tiantian Zou, Wei Qin, Xiaotian Shen, Yinghan Su, Jianhua Li, Yang Chen, Ze Zhang, Haoting Sun, Yan Zheng, Chao-Qun Wang, Zhengxin Wang, Tian-En Li, Shun Wang, Le Zhu, Xufeng Wang, Yan Fu, Xudong Ren, Qiongzhu Dong, Lun-Xiu Qin. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Cancer research.
2022 10; 82(20):3845-3857. doi:
10.1158/0008-5472.can-21-4140. [PMID: 36066408] - Ming-Yu Luo, Ye Zhou, Wei-Ming Gu, Cheng Wang, Ning-Xiang Shen, Jiang-Kai Dong, Hui-Min Lei, Ya-Bin Tang, Qian Liang, Jing-Hua Zou, Lu Xu, Pengfei Ma, Guanglei Zhuang, Ling Bi, Ling Xu, Liang Zhu, Hong-Zhuan Chen, Ying Shen. Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
Cancer research.
2022 Oct; 82(19):3516-3531. doi:
10.1158/0008-5472.can-21-4074. [PMID: 36193649] - Chang Liu, Zhenxing Wang, Qian Liu, Guangyao Wu, Chunhong Chu, Lanxin Li, Lei An, Shaofeng Duan. Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2022 Oct; 24(10):1975-1985. doi:
10.1007/s12094-022-02854-3. [PMID: 35666454] - Leila Asadollahi, Amin Mahoutforoush, Seyed Sina Dorreyatim, Tannaz Soltanfam, Ana Cláudia Paiva-Santos, Diana Peixoto, Francisco Veiga, Hamed Hamishehkar, Mahdi Zeinali, Soheil Abbaspour-Ravasjani. Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation.
International journal of pharmaceutics.
2022 Aug; 624(?):122027. doi:
10.1016/j.ijpharm.2022.122027. [PMID: 35850183] - Chun-Han Tang, Ling Qin, Ying-Chun Gao, Tai-Yu Chen, Ke Xu, Tao Liu, Tao Ren. APE1 shRNA-loaded cancer stem cell-derived extracellular vesicles reverse Erlotinib resistance in non-small cell lung cancer via the IL-6/STAT3 signalling.
Clinical and translational medicine.
2022 05; 12(5):e876. doi:
10.1002/ctm2.876. [PMID: 35605028] - René J Boosman, Cornedine J de Gooijer, Stefanie L Groenland, Jacobus A Burgers, Paul Baas, Vincent van der Noort, Jos H Beijnen, Alwin D R Huitema, Neeltje Steeghs. Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.
Pharmaceutical research.
2022 Apr; 39(4):669-676. doi:
10.1007/s11095-022-03244-8. [PMID: 35352280] - YunQiang Zhang, MingYang Tang, Qiang Guo, HaoQiang Xu, ZhiYong Yang, Dan Li. The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis.
Gene.
2022 Mar; 816(?):146173. doi:
10.1016/j.gene.2021.146173. [PMID: 35026294] - Parimala Devi Ganthala, Sateesh Alavala, Naveen Chella, Sai Balaji Andugulapati, Nagendra Babu Bathini, Ramakrishna Sistla. Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition.
Colloids and surfaces. B, Biointerfaces.
2022 Mar; 211(?):112305. doi:
10.1016/j.colsurfb.2021.112305. [PMID: 34998178] - Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Clinica chimica acta; international journal of clinical chemistry.
2022 Feb; 527(?):1-10. doi:
10.1016/j.cca.2021.12.028. [PMID: 34999058] - Tanveer A Wani, Mohammed M Alanazi, Nawaf A Alsaif, Ahmed H Bakheit, Seema Zargar, Ommalhasan Mohammed Alsalami, Azmat Ali Khan. Interaction Characterization of a Tyrosine Kinase Inhibitor Erlotinib with a Model Transport Protein in the Presence of Quercetin: A Drug-Protein and Drug-Drug Interaction Investigation Using Multi-Spectroscopic and Computational Approaches.
Molecules (Basel, Switzerland).
2022 Feb; 27(4):. doi:
10.3390/molecules27041265. [PMID: 35209054] - Safna Hussan K P, Thekkekara D Babu, Pareeth C M, Greena Joshy, Deepu Mathew, M Shahin Thayyil. Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights.
Free radical research.
2022 Feb; 56(2):196-208. doi:
10.1080/10715762.2022.2065990. [PMID: 35514158] - Rikako Oki, Yosuke Hirakawa, Yasuhiro Oda, Motonobu Nakamura, Kenjiro Honda, Hiroyuki Abe, Yukako Domoto, Naoya Miyashita, Takahide Nagase, Masaomi Nangaku. Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma.
CEN case reports.
2022 02; 11(1):67-72. doi:
10.1007/s13730-021-00632-8. [PMID: 34309804] - Qianfei Cui, Peng Song, Tiancheng Ma, Zefeng Wang, Xiaojing Lu, Yongjia Shi, Fang Zhang, Guoqiang Lin, Jiajia Dong, Jiange Zhang. Discovery of a Novel Potent Antitumor Molecule, P19G1, by Erlotinib Derivative Libraries Synthesized by Modular Click-Chemistry.
Technology in cancer research & treatment.
2022 Jan; 21(?):15330338221109649. doi:
10.1177/15330338221109649. [PMID: 36303409] - Yacine Tandjaoui-Lambiotte, Yanis Akrour, Aude Gibelin, Frederic Gonzalez, Annabelle Stoclin, Anne-Sophie Moreau, Paul Jaubert, Anne Oppenheimer, Boris Duchemann, Stéphane Gaudry. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Chest.
2022 01; 161(1):284-287. doi:
10.1016/j.chest.2021.06.079. [PMID: 34302842] - Hye Jin Choi, So-Jung Park, You Na Choi, Soo-Dam Kim, Eun-Bin Kwag, Si-Yeon Song, Ji Hye Park, Jin Kyu Kim, Changon Seo, Jeong June Choi, Hwa-Seung Yoo. Selective Immune Modulating Activities of Viscum album and Its Components; A Possibility of Therapeutics on Skin Rash Induced by EGFR Inhibitors.
Integrative cancer therapies.
2022 Jan; 21(?):15347354221118332. doi:
10.1177/15347354221118332. [PMID: 36154312] - Yuji Mukai, Azusa Wakamoto, Tae Hatsuyama, Tatsunari Yoshida, Hideki Sato, Akihisa Fujita, Nobuo Inotsume, Takaki Toda. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Therapeutic drug monitoring.
2021 12; 43(6):772-779. doi:
10.1097/ftd.0000000000000895. [PMID: 33871406] - Michelle S Clement, Eva Boysen Fynboe Ebert, Peter Meldgaard, Boe S Sorensen. Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
Clinical lung cancer.
2021 11; 22(6):e870-e877. doi:
10.1016/j.cllc.2021.05.002. [PMID: 34140247] - Hriday Bera, Mohammed A Abosheasha, Yoshihiro Ito, Motoki Ueda. Etherified pullulan-polyethylenimine based nanoscaffolds improved chemosensitivity of erlotinib on hypoxic cancer cells.
Carbohydrate polymers.
2021 Nov; 271(?):118441. doi:
10.1016/j.carbpol.2021.118441. [PMID: 34364579] - Jonathan W Riess, Karen L Reckamp, Paul Frankel, Jeffrey Longmate, Karen A Kelly, David R Gandara, Caroline M Weipert, Victoria M Raymond, Harold N Keer, Philip C Mack, Edward M Newman, Primo N Lara. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
Clinical lung cancer.
2021 11; 22(6):541-548. doi:
10.1016/j.cllc.2021.05.001. [PMID: 34140248] - Ana Catalán-Latorre, Manuel Sureda, Antonio Brugarolas-Masllorens, Vanesa Escudero-Ortiz. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
Therapeutic drug monitoring.
2021 08; 43(4):447-450. doi:
10.1097/ftd.0000000000000894. [PMID: 33840795] - Lucio Litti, Stefano Trivini, Davide Ferraro, Javier Reguera. 3D Printed Microfluidic Device for Magnetic Trapping and SERS Quantitative Evaluation of Environmental and Biomedical Analytes.
ACS applied materials & interfaces.
2021 Jul; 13(29):34752-34761. doi:
10.1021/acsami.1c09771. [PMID: 34256559] - Tae Young Kim, Boram Lee, Yonghyo Kim, Yutaka Sugihara, Melinda Rezeli, A Marcell Szasz, Balazs Dome, Gyorgy Marko-Varga, Ho Jeong Kwon. Matrix-assisted laser desorption ionization - mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non-small-cell lung cancer mouse xenograft model.
Clinical and translational medicine.
2021 07; 11(7):e481. doi:
10.1002/ctm2.481. [PMID: 34323418] - Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Paola Bordi, Michela Verzè, Amir Avan, Marcello Tiseo, Elisa Giovannetti. Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.
Cells.
2021 06; 10(6):. doi:
10.3390/cells10061520. [PMID: 34208765] - Ji Hyeon You, Jaewang Lee, Jong-Lyel Roh. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition.
Cancer letters.
2021 06; 507(?):40-54. doi:
10.1016/j.canlet.2021.03.013. [PMID: 33741422] - Bridget L Morse, John K Fallon, Anil Kolur, Andrew T Hogan, Philip C Smith, Kathleen M Hillgren. Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.
The AAPS journal.
2021 04; 23(3):58. doi:
10.1208/s12248-021-00583-z. [PMID: 33903987] - Yujing Wang, Hang Li, Chu Xue, Hao Chen, Yanning Xue, Fang Zhao, Michael X Zhu, Zhengyu Cao. TRPV3 enhances skin keratinocyte proliferation through EGFR-dependent signaling pathways.
Cell biology and toxicology.
2021 04; 37(2):313-330. doi:
10.1007/s10565-020-09536-2. [PMID: 32535744] - X Zhang, C Xue, J Li, J Zhang, K Tan, X Jiang, H Zheng, H Dong, Y Yu, Z Hu, H Cui. [Establishment of animal models of epidermal growth factor receptor inhibitor-related rashes].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2021 Mar; 41(3):352-357. doi:
10.12122/j.issn.1673-4254.2021.03.06. [PMID: 33849825] - Lu Wang, Zourong Ruan, Dandan Yang, Yin Hu, Jian Liang, Jinliang Chen, Rong Shao, Yichao Xu, Yanlu Guan, Bo Jiang. Pharmacokinetics and Bioequivalence Evaluation of Erlotinib Hydrochloride Tablets: Randomized, Open-Label, 2-Period Crossover Study in Healthy Chinese Subjects.
Clinical pharmacology in drug development.
2021 02; 10(2):166-172. doi:
10.1002/cpdd.811. [PMID: 32416055] - R B Verheijen, T T van Duijl, M M van den Heuvel, D Vessies, M Muller, J H Beijnen, J M Janssen, J H M Schellens, N Steeghs, D van den Broek, A D R Huitema. Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Cancer chemotherapy and pharmacology.
2021 02; 87(2):269-276. doi:
10.1007/s00280-021-04230-4. [PMID: 33484280] - Weigang Zhao, Tangbing Chen, Chunyu Ji, Liwen Xiong, Rong Li, Baohui Han, Wentao Fang. Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas.
The Annals of thoracic surgery.
2021 01; 111(1):290-295. doi:
10.1016/j.athoracsur.2020.04.133. [PMID: 32569671] - Qian Liang, Wei-Ming Gu, Ke Huang, Ming-Yu Luo, Jing-Hua Zou, Guang-Lei Zhuang, Hui-Min Lei, Hong-Zhuan Chen, Liang Zhu, Lu Zhou, Ying Shen. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Acta pharmacologica Sinica.
2021 Jan; 42(1):115-119. doi:
10.1038/s41401-020-0399-1. [PMID: 32404981] - Jin-Zhao Yang, Yi Song, Jian-Hua Xiong, Yu-Xian Lin, Congcong Wen, Yu Li, Yunfang Zhou. The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.
BioMed research international.
2021; 2021(?):6679082. doi:
10.1155/2021/6679082. [PMID: 34195278] - Xiaowen Zhou, Bojia Liu, Qing Ning, Zhi Xia, Rongling Zhong, Li Zhang, Lei Wu. Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.
Oncology reports.
2021 01; 45(1):217-229. doi:
10.3892/or.2020.7848. [PMID: 33200228] - Shuo Li, Linping Ke, Xue Meng, Haiyan Zhou, Xiqin Zhang, Huaguo Wu, Jinming Yu, Hui Zhang. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Recent patents on anti-cancer drug discovery.
2021; 16(1):108-116. doi:
10.2174/1574892815666201127114224. [PMID: 33245275] - Tsutomu Shimada, Mai Okano, Momoko Yamada, Yuki Ogawa, Arimi Ueda, Katsuhiko Nagase, Yoshimichi Sai. Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression.
Drug metabolism and pharmacokinetics.
2020 Dec; 35(6):534-538. doi:
10.1016/j.dmpk.2020.08.003. [PMID: 33028492] - Kaname Nosaki, Takeharu Yamanaka, Akinobu Hamada, Yoshimasa Shiraishi, Taishi Harada, Daisuke Himeji, Takeshi Kitazaki, Noriyuki Ebi, Takayuki Shimose, Takashi Seto, Mitsuhiro Takenoyama, Kenji Sugio. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
The oncologist.
2020 12; 25(12):e1869-e1878. doi:
10.1634/theoncologist.2020-0640. [PMID: 32654250] - Ryo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, Toshikazu Yamaguchi, Ken Uchibori, Satoru Kitazono, Naoya Fujita, Ryohei Katayama, Makoto Nishio. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Cancer chemotherapy and pharmacology.
2020 10; 86(4):517-525. doi:
10.1007/s00280-020-04136-7. [PMID: 32948919] - Ying Li, Ying Liu, Bin Du, Genyang Cheng. Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem.
Molecular pharmaceutics.
2020 09; 17(9):3151-3164. doi:
10.1021/acs.molpharmaceut.0c00077. [PMID: 32787273] - Sheng-Li Cho, Wei-Chou Lin, Chieh-An Chuang, Wei-Yu Liao, Chun-Fu Lai. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
Nephrology (Carlton, Vic.).
2020 09; 25(9):730. doi:
10.1111/nep.13721. [PMID: 32364270] - Wee Kiat Tan, Alyssa Rui Yi Tan, Punitha Sivanandam, Ernest Jing Hui Goh, Ze Ping Yap, Nur Fazilah Saburulla, Karl Austin-Muttitt, Jonathan G L Mullins, Aik Jiang Lau. In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
The Journal of pharmacology and experimental therapeutics.
2020 08; 374(2):295-307. doi:
10.1124/jpet.120.265249. [PMID: 32393528] - Zhi-Xing Cao, Chuan-Jie Guo, Xiaominting Song, Jun-Lin He, Lu Tan, Si Yu, Ruo-Qi Zhang, Fu Peng, Cheng Peng, Yu-Zhi Li. Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2020 08; 34(8):10182-10190. doi:
10.1096/fj.201902922rr. [PMID: 32543003] - Tomonobu Uchino, Hiyori Fujino, Daichi Kamiya, Tomonori Suzuki, Yasunori Miyazaki, Kazuhiro Asada, Toshihiro Shirai, Hiroaki Yagi, Yuko Sano, Mutsumi Moriki, Hajime Mizuno, Kenichiro Todoroki, Midori Kimura, Yoshiyuki Kagawa. Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration.
Cancer chemotherapy and pharmacology.
2020 08; 86(2):233-243. doi:
10.1007/s00280-020-04095-z. [PMID: 32666159] - Toshio Shimizu, Kazuto Nishio, Kazuko Sakai, Isamu Okamoto, Kunio Okamoto, Masayuki Takeda, Maiko Morishita, Kazuhiko Nakagawa. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology.
2020 08; 86(2):211-219. doi:
10.1007/s00280-020-04112-1. [PMID: 32638093] - Shingo Miyamoto, Koichi Azuma, Hidenobu Ishii, Akihiro Bessho, Shinobu Hosokawa, Nobuaki Fukamatsu, Hideo Kunitoh, Mari Ishii, Hiroshi Tanaka, Hiromi Aono, Yoshiro Nakahara, Kei Kusaka, Yukio Hosomi, Norihiro Kikuchi, Yoshiaki Mori, Hidetoshi Itani, Akinobu Hamada, Kazuhiko Yamada, Hiroaki Okamoto. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
JAMA oncology.
2020 07; 6(7):e201250. doi:
10.1001/jamaoncol.2020.1250. [PMID: 32407455] - Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo. Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
EBioMedicine.
2020 Jul; 57(?):102861. doi:
10.1016/j.ebiom.2020.102861. [PMID: 32629391] - Sanju Sinha, Kuoyuan Cheng, Alejandro A Schäffer, Kenneth Aldape, Eyal Schiff, Eytan Ruppin. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.
Molecular systems biology.
2020 07; 16(7):e9628. doi:
10.15252/msb.20209628. [PMID: 32729248] - Evelina Cardoso, Monia Guidi, Nihel Khoudour, Pascaline Boudou-Rouquette, Elizabeth Fabre, Camille Tlemsani, Jennifer Arrondeau, François Goldwasser, Michel Vidal, Marie Paule Schneider, Anna Dorothea Wagner, Nicolas Widmer, Benoit Blanchet, Chantal Csajka. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Clinical therapeutics.
2020 07; 42(7):1302-1316. doi:
10.1016/j.clinthera.2020.05.008. [PMID: 32631634] - Marzia Del Re, Iacopo Petrini, Francesca Mazzoni, Simona Valleggi, Giulia Gianfilippo, Daniele Pozzessere, Antonio Chella, Stefania Crucitta, Eleonora Rofi, Giuliana Restante, Mario Miccoli, Marina Chiara Garassino, Romano Danesi. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Clinical lung cancer.
2020 05; 21(3):232-237. doi:
10.1016/j.cllc.2019.10.003. [PMID: 31735523] - Juntao Pang, Huaixin Xing, Yingui Sun, Shuo Feng, Suzhen Wang. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 May; 125(?):109861. doi:
10.1016/j.biopha.2020.109861. [PMID: 32070872] - Fatih Selcukbiricik, Elif Ozdogan, Tuncay Dagel, Serhan Tanju, Suat Erus, Lale A Ertuglu, Murat Kapdağlı, Deniz Tural, Ahmet Bilici, Sukru Dilege, Nil M Mandel, Mehmet Kanbay. Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer.
Journal of clinical pharmacy and therapeutics.
2020 Apr; 45(2):303-308. doi:
10.1111/jcpt.13071. [PMID: 31778239] - Liwen Xiong, Yuqing Lou, Hao Bai, Rong Li, Jinjing Xia, Wentao Fang, Jie Zhang, Han Han-Zhang, Analyn Lizaso, Bing Li, Aiqin Gu, Baohui Han. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
The Journal of international medical research.
2020 Apr; 48(4):300060519887275. doi:
10.1177/0300060519887275. [PMID: 31885349] - Jean-Luc Raoul, Julien Edeline, Marine Gilabert, Hélène Senellart, Jean-Sébastien Frenel. [Proton pump inhibitors and cancers: A hazardous association?].
Bulletin du cancer.
2020 Apr; 107(4):458-464. doi:
10.1016/j.bulcan.2019.12.009. [PMID: 32057465] - Xiaodong Liu, Yu Bai, Xiaoming Zhou, Xiu Gu, Li Zhao. Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib.
Journal of clinical pharmacy and therapeutics.
2020 Apr; 45(2):388-393. doi:
10.1111/jcpt.13078. [PMID: 31730733] - Yuping Liu, Haiyan Xing, Xiangliang Jiang, Yan Chen, Mengmeng Huang, Suyun Yu. Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Mar; 123(?):109755. doi:
10.1016/j.biopha.2019.109755. [PMID: 31926375] - Xin Li, Minghui Liu, Hongbing Zhang, Hongyu Liu, Jun Chen. Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Thoracic cancer.
2020 03; 11(3):819-826. doi:
10.1111/1759-7714.13303. [PMID: 31918452] - Céline Greco, Stéphanie Leclerc-Mercier, Sarah Chaumon, François Doz, Smail Hadj-Rabia, Thierry Molina, Claude Boucheix, Christine Bodemer. Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.
JAMA dermatology.
2020 02; 156(2):191-195. doi:
10.1001/jamadermatol.2019.4126. [PMID: 31895432] - Joanna J Chmielinska, Jay H Kramer, I-Tong Mak, Christopher F Spurney, William B Weglicki. Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.
Molecular and cellular biochemistry.
2020 Feb; 465(1-2):175-185. doi:
10.1007/s11010-019-03677-7. [PMID: 31853800] - Hye Duck Choi, Min Jung Chang. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
PloS one.
2020; 15(7):e0234818. doi:
10.1371/journal.pone.0234818. [PMID: 32663210] - Renaud Grépin, Mélanie Guyot, Aurore Dumond, Jérôme Durivault, Damien Ambrosetti, Jean-François Roussel, Florence Dupré, Hervé Quintens, Gilles Pagès. The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.
Theranostics.
2020; 10(3):1107-1121. doi:
10.7150/thno.38346. [PMID: 31938054] - Na Yin, Hui Yu, Xiaodi Zhang, Xiaodan Lv. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Drug design, development and therapy.
2020; 14(?):4465-4475. doi:
10.2147/dddt.s270303. [PMID: 33122890] - Go Makimoto, Kadoaki Ohashi, Shuta Tomida, Kazuya Nishii, Takehiro Matsubara, Hiroe Kayatani, Hisao Higo, Kiichiro Ninomiya, Akiko Sato, Hiromi Watanabe, Hirohisa Kano, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Minoru Takata, Yoshinobu Maeda, Katsuyuki Kiura. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019 11; 14(11):2009-2018. doi:
10.1016/j.jtho.2019.07.017. [PMID: 31374369] - J Gao, H-R Li, C Jin, J-H Jiang, J-Y Ding. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2019 Oct; 21(10):1287-1301. doi:
10.1007/s12094-019-02075-1. [PMID: 30864018] - Siow Ming Lee, Sunil Upadhyay, Conrad Lewanski, Stephen Falk, Geraldine Skailes, Penella J Woll, Matthew Hatton, Rohit Lal, Richard Jones, Elizabeth Toy, Robin Rudd, Yenting Ngai, Alex Edwards, Allan Hackshaw. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
European journal of cancer (Oxford, England : 1990).
2019 10; 120(?):86-96. doi:
10.1016/j.ejca.2019.07.025. [PMID: 31499384] - Yeonjoo Choi, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Dalyong Kim, Jong Gwon Choi, Ja Young Seo, Inkeun Park, Jae Lyun Lee. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
Cancer research and treatment.
2019 Oct; 51(4):1549-1556. doi:
10.4143/crt.2019.086. [PMID: 30913859] - Makoto Hiraide, Yuichi Minowa, Yasuhiro Nakano, Kenichi Suzuki, Taro Shiga, Makoto Nishio, Junya Miyoshi, Harumi Takahashi, Toshihiro Hama. Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2019 Oct; 25(7):1599-1607. doi:
10.1177/1078155218801061. [PMID: 30253730] - Samuel J Reddick, Olivia Campagne, Jie Huang, Arzu Onar-Thomas, Alberto Broniscer, Amar Gajjar, Clinton F Stewart. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
Cancer chemotherapy and pharmacology.
2019 10; 84(4):829-838. doi:
10.1007/s00280-019-03921-3. [PMID: 31392390] - Ming-Zhi Zhang, Kensuke Sasaki, Yan Li, Zhilian Li, Yu Pan, Guan-Nan Jin, Yinqiu Wang, Aolei Niu, Suwan Wang, Xiaofeng Fan, Jian Chun Chen, Corina Borza, Haichun Yang, Ambra Pozzi, Agnes B Fogo, Raymond C Harris. The Role of the EGF Receptor in Sex Differences in Kidney Injury.
Journal of the American Society of Nephrology : JASN.
2019 09; 30(9):1659-1673. doi:
10.1681/asn.2018121244. [PMID: 31292196] - Andrew McKinney, Olle R Lindberg, Jane R Engler, Katharine Y Chen, Anupam Kumar, Henry Gong, Kan V Lu, Erin F Simonds, Timothy F Cloughesy, Linda M Liau, Michael Prados, Andrew W Bollen, Mitchel S Berger, Joseph T C Shieh, C David James, Theodore P Nicolaides, William H Yong, Albert Lai, Monika E Hegi, William A Weiss, Joanna J Phillips. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
Molecular cancer therapeutics.
2019 09; 18(9):1565-1576. doi:
10.1158/1535-7163.mct-18-1330. [PMID: 31270152] - C Louwrens Braal, G D Marijn Veerman, Robert Peric, Joachim G J V Aerts, Ron H J Mathijssen, Stijn L W Koolen, Peter de Bruijn. Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application.
Journal of pharmaceutical and biomedical analysis.
2019 Aug; 172(?):175-182. doi:
10.1016/j.jpba.2019.04.031. [PMID: 31051406] - Anna Svedberg, Svante Vikingsson, Anders Vikström, Niels Hornstra, Magnus Kentson, Eva Branden, Hirsh Koyi, Bengt Bergman, Henrik Gréen. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
British journal of clinical pharmacology.
2019 08; 85(8):1704-1709. doi:
10.1111/bcp.13953. [PMID: 30945322] - Fang Zheng, YueYang Zhao, Xiong Li, Qing Tang, JingJing Wu, WanYin Wu, Swei Sunny Hann. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Journal of ethnopharmacology.
2019 Jul; 239(?):111928. doi:
10.1016/j.jep.2019.111928. [PMID: 31077779] - Anna A Kiseleva, Vladislav A Korobeynikov, Anna S Nikonova, Peishan Zhang, Petr Makhov, Alexander Y Deneka, Margret B Einarson, Ilya G Serebriiskii, Hanqing Liu, Jeffrey R Peterson, Erica A Golemis. Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019 07; 25(13):4179-4193. doi:
10.1158/1078-0432.ccr-18-3535. [PMID: 30867219] - Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
BMC urology.
2019 Jun; 19(1):51. doi:
10.1186/s12894-019-0484-2. [PMID: 31182090] - Consuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V Scagliotti. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
The oncologist.
2019 06; 24(6):e251-e259. doi:
10.1634/theoncologist.2018-0089. [PMID: 30139835] - Aya Manabe, Chisa Furukawa, Hajime Hasegawa, Toshiyuki Matsunaga, Satoshi Endo, Akira Ikari. Upregulation of transient receptor potential melastatin 6 channel expression by rosiglitazone and all-trans-retinoic acid in erlotinib-treated renal tubular epithelial cells.
Journal of cellular physiology.
2019 06; 234(6):8951-8962. doi:
10.1002/jcp.27565. [PMID: 30461012] - Tian Wang, Dexing Wang, Lian Zhang, Ping Yang, Jing Wang, Qi Liu, Fei Yan, Feng Lin. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Journal of experimental & clinical cancer research : CR.
2019 May; 38(1):226. doi:
10.1186/s13046-019-1195-y. [PMID: 31138318] - Martin Bauer, Rudolf Karch, Beatrix Wulkersdorfer, Cécile Philippe, Lukas Nics, Eva-Maria Klebermass, Maria Weber, Stefan Poschner, Helmuth Haslacher, Walter Jäger, Nicolas Tournier, Wolfgang Wadsak, Marcus Hacker, Markus Zeitlinger, Oliver Langer. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019 04; 60(4):486-491. doi:
10.2967/jnumed.118.216432. [PMID: 30237210] - Yuping Liu, Xiangliang Jiang, Yue Gu, Yan Chen. Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
International immunopharmacology.
2019 Apr; 69(?):79-87. doi:
10.1016/j.intimp.2019.01.023. [PMID: 30682720] - Alexander Traxl, Severin Mairinger, Thomas Filip, Michael Sauberer, Johann Stanek, Stefan Poschner, Walter Jäger, Viktoria Zoufal, Gaia Novarino, Nicolas Tournier, Martin Bauer, Thomas Wanek, Oliver Langer. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.
Molecular pharmaceutics.
2019 03; 16(3):1282-1293. doi:
10.1021/acs.molpharmaceut.8b01217. [PMID: 30694684] - H Rudolf de Boer, Martin Pool, Esméé Joosten, Marieke Everts, Douwe F Samplonius, Wijnand Helfrich, Harry J M Groen, Suzanne van Cooten, Fabrizia Fusetti, Rudolf S N Fehrmann, Elisabeth G E de Vries, Marcel A T M van Vugt. Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.
Oncogene.
2019 02; 38(9):1477-1488. doi:
10.1038/s41388-018-0522-7. [PMID: 30305724] - Hadir M Maher, Aliyah Almomen, Nourah Z Alzoman, Shereen M Shehata, Amal Al-Subaie. A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction.
BioMed research international.
2019; 2019(?):2410845. doi:
10.1155/2019/2410845. [PMID: 31871933] - Katsuko Kikuchi, Keiko Nozawa, Naoya Yamazaki, Yasuo Nakai, Ayaka Higashiyama, Masayuki Asano, Yutaka Fujiwara, Shintaro Kanda, Yuichiro Ohe, Atsuo Takashima, Narikazu Boku, Akira Inoue, Masanobu Takahashi, Takahiro Mori, Osamu Taguchi, Yasuhiro Inoue, Hitoshi Mizutani. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
The Journal of dermatology.
2019 Jan; 46(1):18-25. doi:
10.1111/1346-8138.14691. [PMID: 30402978] - Lucio Litti, Andrea Ramundo, Francesca Biscaglia, Giuseppe Toffoli, Marina Gobbo, Moreno Meneghetti. A surface enhanced Raman scattering based colloid nanosensor for developing therapeutic drug monitoring.
Journal of colloid and interface science.
2019 Jan; 533(?):621-626. doi:
10.1016/j.jcis.2018.08.107. [PMID: 30193149] - Michael McMahon, Shaohong Ding, Lourdes Acosta Jimenez, Remi Terranova, Marie-Apolline Gerard, Antonio Vitobello, Jonathan Moggs, Colin J Henderson, C Roland Wolf. Constitutive androstane receptor 1 is constitutively bound to chromatin and 'primed' for transactivation in hepatocytes.
Molecular pharmacology.
2019 01; 95(1):97-105. doi:
10.1124/mol.118.113555. [PMID: 30361333] - Xiaohua Gu, Qiang Zhang, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo, Betty Su, Bin Wu. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lung cancer (Amsterdam, Netherlands).
2019 01; 127(?):84-89. doi:
10.1016/j.lungcan.2018.11.029. [PMID: 30642557] - Chia-Ling Li, Te-Chun Hsia, Chia-Hsiang Li, Ko-Jung Chen, Yao-Hsu Yang, Su-Tso Yang. Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study.
Integrative cancer therapies.
2019 Jan; 18(?):1534735419827079. doi:
10.1177/1534735419827079. [PMID: 30836771] - Masahiro Ohgami, Takayuki Kaburagi, Atsuhiko Kurosawa, Kosuke Doki, Toshihiro Shiozawa, Nobuyuki Hizawa, Masato Homma. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
Therapeutic drug monitoring.
2018 12; 40(6):699-704. doi:
10.1097/ftd.0000000000000552. [PMID: 29995672] - Yi-Long Wu, Victor Lee, Chong-Kin Liam, Shun Lu, Keunchil Park, Vichien Srimuninnimit, Jie Wang, Caicun Zhou, Anita Appius, Peter Button, Gregory Hooper, John F Palma, Katja Schulze, Sidney Scudder, David S Shames, Anny-Yue Yin, Guili Zhang, Tony Mok. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Lung cancer (Amsterdam, Netherlands).
2018 12; 126(?):1-8. doi:
10.1016/j.lungcan.2018.10.004. [PMID: 30527172] - Cierra N Sharp. Cisplatin Effects in Lung Adenocarcinoma-bearing Mice, Alone and in Combination with Erlotinib.
Toxicologic pathology.
2018 12; 46(8):1049-1050. doi:
10.1177/0192623318798342. [PMID: 30189778] - Haoping Xu, Changyu He, Ying Liu, Jinling Jiang, Tao Ma. Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations.
Artificial cells, nanomedicine, and biotechnology.
2018 Dec; 46(8):1902-1907. doi:
10.1080/21691401.2017.1396222. [PMID: 29081246] - Tatsuya Kato, Cheng S Jin, Daiyoon Lee, Hideki Ujiie, Kosuke Fujino, Hsin-Pei Hu, Hironobu Wada, Licun Wu, Juan Chen, Rober A Weersink, Hiromi Kanno, Yutaka Hatanaka, Kanako C Hatanaka, Kichizo Kaga, Yoshiro Matsui, Yoshihiro Matsuno, Marc De Perrot, Brian C Wilson, Gang Zheng, Kazuhiro Yasufuku. Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
International journal of oncology.
2018 Nov; 53(5):2034-2046. doi:
10.3892/ijo.2018.4555. [PMID: 30226590] - Guanghui Ji, Chenyang Zhang, Shan Guan, Xiangying Yao. Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature.
Clinical breast cancer.
2018 10; 18(5):e759-e765. doi:
10.1016/j.clbc.2018.07.022. [PMID: 30177482]